Panacea Global, Inc.

January 21, 2013 16:24 ET

Panacea Global Announces Its Official Partnership With UICC

TORONTO, ONTARIO--(Marketwire - Jan. 21, 2013) - Panacea Global, Inc. ("Panacea") (OTCBB:PANG) a biotechnology company focused on the discovery, development and commercialization of diagnostic products for the management of cancer, announced today that it has joined the Union for International Cancer Control (UICC) in an international partnership also known as its Champions Programme.

UICC works in partnership with corporations and organizations through its Champions programme to support priority programmes that benefit the global cancer community and drive action on a global scale. Other notable partners include Bayer, Roche, GSK, Sanofi and a number of their member organizations.

"We are privileged to be given the opportunity to join this prestigious organization that is playing an important role in fight against cancer", commented Dr. Moshiri, Panacea's President and CEO. "This partnership will be valuable to Panacea's plans to further promote its revolutionary cancer diagnostic technology within the global medical community.

Panacea Global's President & CEO, Dr. Moshiri has had the honour of joining UICC's most recent global roundtable meeting held on January 16th, 2013 in Washington D.C. The roundtable event was co-hosted by the UICC and the American Society of Clinical Oncology (ASCO) on the topic of personalized medicine.

About the Union for International Cancer Control (UICC)

The Union for International Cancer Control (UICC) is a membership organization that exists to help the global health community accelerate the fight against cancer. Founded in 1933 and based in Geneva, Switzerland, UICC's growing membership of over 760 organizations across 155 countries, features the world's major cancer societies, ministries of health, research institutes and patient groups. Together with its members, key partners, the World Health Organization, World Economic Forum and others, UICC is tackling the growing cancer crisis on a global scale. For more information, please visit

About Panacea Global

Panacea Global is a biotechnology company focused on the development and commercialization of diagnostic products for the management of cancer. Panacea has developed an accurate, timely, cost effective and non-invasive early cancer detection test to increase the quality of life of cancer patients and ultimately saving lives. Panacea's test is based on the detection of the human aspartyl (asparaginyl) β-hydroxylase (HAAH), a novel biomarker expressed in malignant cancer cells in patients' blood samples. Panacea Global has the exclusive worldwide (excluding the USA) rights to HAAH-based cancer tests. More information about Panacea Global (OTCBB:PANG) is available at

Forward-looking statements

Certain information contained in this document may include "forward-looking information". Without limiting the foregoing, the information and any forward-looking information may include statements regarding projects, costs, objectives and future returns of the Company or hypotheses underlying these items. In this document, words such as "may", "would", "could", "will", "likely", "believe", "expect", "anticipate", "intend", "plan", "estimate" and similar words and the negative form thereof are used to identify forward-looking statements. Forward-looking statements should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether, or the times at or by which, such future performance will be achieved. Forward-looking statements and information are based on information available at the time and/or the Company management's good-faith beliefs with respect to future events and are subject to known or unknown risks, uncertainties, assumptions and other unpredictable factors, many of which are beyond the Company's control. The Company does not intend, nor does it undertake, any obligation to update or revise any forward-looking information or statements contained in this document to reflect subsequent information, events or circumstances or otherwise, except as required by applicable laws.

Contact Information